Solara Active Pharma Sciences Limited has informed the Exchange regarding a press release dated October 16, 2026, titled "Solara s Q2 FY27 revenue grows 33% to INR 4,178 Mn and EBITDA more than doubles to INR 769 Mn, its best quarter in five years".

Summary by 6ix AI

The company reported a substantial increase in revenue and EBITDA, marking its best quarter in five years, with improvements across all business segments. The base business revenue rose significantly year-over-year, contributing to the overall positive financial performance, while the Ibuprofen segment showed signs of recovery. The press release also indicates a notable reduction in net debt, enhancing the company's financial stability and capacity for future investments.

Written by 6ix AI from the company’s filing. How 6ix writes summaries